Compound ID | 1237
ETX0282CPDP (ETX0282 + cefpodoxime)
Synonym(s): ETX0282/Cefpodoxime
Class: Beta-lactam + beta-lactamase inhibitor
| Agent Type: | Semisynthetic; Small molecule; Direct acting; Antibiotic adjuvant; |
| Spectrum of activity: | Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Beta-lactamase inhibitor |
| Target Pathogen: | Active against pathogens causing complicated UTIs (Enterobacteriaceae including ESBL-producing and CRE) |
| Combined with other compounds: | Yes |
| Institute where first reported: | Entasis Therapeutics |
| Highest development stage: | Phase 1 |
| Development status: | Active |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/6335986#section=3D-Conformer |
| Guide to Pharmacology: | ETX0282 |
| Citation: | https://doi.org/10.1021/acs.jmedchem.0c00579 |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.